Hook & thesis
DexCom is no longer a pure-growth story priced for perfection. The company reported a Q3 beat with revenue of $1.34 billion and adjusted EPS of $0.73, outpacing expectations and showing meaningful margin recovery. Management raised full-year 2026 revenue guidance to $5.20-$5.25 billion and authorized an additional $1 billion share buyback - clear signals that the company is generating cash and prioritizing shareholder returns.
We view improved patient access - via broader reimbursement and stronger clinical evidence for the G7 system - as the primary durable driver of revenue and margin upside. At the current price of $82.31 the market offers an attractive entry for a long-term trade: the fundamentals justify a patient accumulation into weakness, with a clear stop and a target that reflects both the near-term operating improvement and the longer-term growth runway for continuous glucose monitoring (CGM).
What DexCom does and why the market should care
DexCom designs and commercializes continuous glucose monitoring systems for people with diabetes. Its product family includes the G6, the newer G7, and related digital services and APIs that integrate CGM data into routine care and remote monitoring workflows. CGM moves diabetes care from episodic fingersticks to continuous, actionable data that clinicians and patients can use to manage medications, dosing and lifestyle - and to reduce hypoglycemia risk.
The timing matters: payers and clinicians are increasingly comfortable prescribing CGM to a broader set of patients, including many with Type 2 diabetes. The company's CONNECT study for G7 showed a clinically meaningful 1.6% A1C reduction in non-insulin-treated Type 2 patients and 97% adherence at 26 weeks, which strengthens the reimbursement and physician adoption case. As reimbursement widens and GLP-1 use in Type 2 expands, CGM becomes a logical complement for titration and safety monitoring - enlarging DexCom's addressable market.
Recent results and the numbers that matter
Key takeaways from the quarter:
- Revenue: $1.34 billion in Q3, up 11.2% year-over-year, with U.S. revenues up 13.8%.
- Profitability: adjusted EPS of $0.73, beating estimates by roughly 10.6%, and adjusted gross margin expanded 380 basis points to 65.1%.
- Guidance: raised full-year revenue outlook to $5.20-$5.25 billion and an additional $1 billion share buyback was authorized.
- Cash generation: free cash flow of $1.0983 billion on an enterprise value of roughly $30.97 billion (EV), supporting capital returns and reinvestment.
Valuation context: the company trades at roughly $82.31 per share with a market cap near $31.06 billion and a trailing price-to-earnings near 31x. EV/EBITDA is approximately 20.7x and EV/Sales near 6.07x. Those multiples are elevated relative to a defensive medical-device name, but DexCom's margin profile - gross margin at 65.1% and operating profit expansion - plus strong free cash flow justify a premium if top-line growth and reimbursement rollout continue.
Technical and market structure notes
On the tape, shares have traded between a 52-week low of $54.11 and a high of $92.59. Current momentum is mixed: 50-day SMA sits near $85.82 while the 10-day SMA is $80.62; RSI is neutral at ~47.7. Short interest has been material but not extreme, with days to cover oscillating around four days most recently. That means directional moves can become self-reinforcing, but short squeezes are not a dominant ongoing risk.
Valuation framing - why today's multiple is defendable
At a market cap of roughly $31 billion, DexCom commands premium multiples because it combines (1) recurring sensor and transmitter revenue, (2) durable clinical value that supports reimbursement expansion, and (3) strong unit economics with gross margins north of 65%. Free cash flow near $1.1 billion gives management optionality to buy back stock ($1B buyback authorized), invest in international growth, and fund manufacturing capacity.
If DexCom can sustain mid-teens revenue growth while maintaining current margins, the current multiple sits within a reasonable range for a high-margin, high-cash-conversion med-tech leader. The counterpoint: multiples require execution - if manufacturing costs or reimbursement slip, downside is real. We account for that in our stop-loss placement below.
Catalysts (what will make the thesis play out)
- Broader reimbursement rollouts in international markets and additional payer coverage in the U.S. for Type 2 patients on GLP-1s or other oral agents.
- Continued G7 adoption driven by the CONNECT data showing adherence and A1C improvement, converting more non-insulin Type 2 patients to CGM use.
- Margin tailwinds as Ireland manufacturing ramp normalizes and prior-year comparisons abate, sustaining gross margins above 60%.
- Share buybacks and continued strong free cash flow, which can support EPS growth even if revenue growth decelerates temporarily.
Trade plan - actionable entry, stop, and target
Trade direction: Long.
Entry price: $82.31 (current market price).
Stop loss: $68.00 - this reflects a break in the technical structure below the recent trading range and protects capital if reimbursement or margin headlines deteriorate.
Target price: $120.00 - this target equates to a multiple expansion and upside consistent with sustained margin and revenue improvement over a longer cycle.
Horizon: long term (180 trading days). I expect the primary drivers - reimbursement expansion and greater patient starts on G7 - to play out over multiple quarters. Shorter checkpoints are useful: short term (10 trading days) for entry discipline and monitoring of news flow; mid term (45 trading days) to evaluate early adoption metrics and any international reimbursement updates. But the trade is built to be held for up to 180 trading days to let fundamentals and buybacks compound.
Position sizing and risk management
Given the company's valuation and the potential for headline-driven volatility, limit an individual position to a size consistent with a medium-risk allocation in a diversified portfolio. Use the $68 stop to define the dollar risk per share and scale in on intraday weakness or pullbacks to the low $70s, rather than averaging up.
Risks and counterarguments
- Reimbursement setbacks - broader adoption in Type 2 hinges on payer decisions. If national payers delay coverage or impose restrictive criteria, new-patient starts could slow and international comparisons could remain unfavorable.
- Manufacturing cost pressure - the company cited factory ramp-related costs and input-cost headwinds previously. If incremental costs persist or Ireland ramp continues to underperform, margin expansion could stall.
- Competition - Abbott and established insulin-delivery players are extending CGM offerings. Faster competitive price or feature moves could compress DexCom's pricing power in certain segments.
- Valuation sensitivity - trading at roughly 31x earnings and EV/EBITDA ~20.7x, the stock is susceptible to multiple contraction if growth decelerates; macro weakness could exacerbate this risk.
- Counterargument: the market is currently pricing in continued adoption and margin improvements. If G7 uptake slows or payer coverage stalls, the multiple could re-rate lower quickly - making the name more of a value trap than a growth compounder.
What would change my mind?
I will become more bullish if management provides clear evidence of accelerating international reimbursement (specific country rollouts), sequential improvement in new-patient starts outside the U.S., and sustained margin expansion with operating leverage. Conversely, I will become more cautious if (1) international reimbursements remain weak into early 2027, (2) manufacturing cost overruns persist and gross margins slip below 60%, or (3) clinical adoption stalls despite strong CONNECT data - any of which would trigger tighter stops or a position reduction.
Bottom line
DexCom is a patient-access story with tangible evidence the adoption levers are turning in its favor: a Q3 beat, gross margin expansion to 65.1%, raised revenue guidance, and a $1 billion buyback. Those elements, together with a strong CONNECT data set for G7 and meaningful free cash flow generation, support a long-term buy around $82.31 with a $68 stop and a $120 target over a 180-trading-day horizon. Execution risks - reimbursement, manufacturing, and competition - are real and merit disciplined position sizing and active monitoring, but the setup offers a compelling, actionable trade for investors willing to hold through the operating cadence required for payer and patient adoption to materialize.
| Metric | Value |
|---|---|
| Current price | $82.31 |
| Market cap | $31.06B |
| Q3 revenue | $1.34B (up 11.2% YoY) |
| Adjusted EPS (Q3) | $0.73 |
| Gross margin | 65.1% |
| Free cash flow | $1.098B |
Trade idea: Buy DexCom at $82.31, stop $68.00, target $120.00. Hold for up to 180 trading days, monitor reimbursement and margin headlines closely.